Lunai Bioworks Inc. (RENB) Stock

About Lunai Bioworks Inc.

Lunai Bioworks, Inc. functions as a pre-clinical stage biotechnology enterprise, concentrating its efforts on pioneering genetically modified cell and immunotherapeutic platforms. These advanced technologies are aimed at providing treatments for a range of infectious diseases and oncological conditions. The company's development pipeline features several candidates, specifically ENOB-HV-01, ENOB-HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. Founded on January 18, 2011, by Rene Sindlev and Serhat Gumrukcu, Lunai Bioworks maintains its corporate base in Los Angeles, California.

Lunai Bioworks Inc. is headquartered in US.

Lunai Bioworks Inc. (RENB) stock trades at $1.42 with a market capitalization of $32.92M. The stock is valued at a price-to-earnings (P/E) ratio of 0.67, a negative price-to-book of -3.72, reflecting negative shareholders' equity, price-to-sales of 170.61. Over the past 52 weeks the stock has ranged between $1.12 and $21.00, and currently trades 93.2% below its 52-week high.

On profitability, Lunai Bioworks Inc. generates a return on equity (ROE) of 892.52% (not meaningful, as shareholders' equity is negative), return on capital employed of 900.00%.

Official website: renovarogroup.com